Ketosteril

ApprovedSmall molecule

FFresenius

Ketosteril is one of 109 small molecule programs targeting Diabetic Nephropathy. It is currently in Approved.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyActive, not recruiting

Nephrotic SyndromeActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Diabetic NephropathyApproved

Active, not recruiting

Nephrotic SyndromePhase 3

Active, not recruiting

Chronic Kidney DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Ketosteril

FFresenius

Approved

2 2

Aranesp

Amgen

Preclinical

40 3

Uloric

Takeda

Preclinical

3 4

Lorelco

Sanofi

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Glucotrol

Pfizer

Preclinical

1 7

Flomax

Sanofi

Preclinical

—8

Miochol

BBausch Health Americas, Inc.

Preclinical

2 9

Epoetin Beta

Roche

Preclinical

5 10

Genotropin

EMD Serono

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Nephrotic Syndrome

NCT05716880

Clinical

Trials by Indication[1]

Chronic Kidney Disease2 trials

Early Detection, Remote Augmented Reality Combined Rehabilitation Therapy, and Translational Therapy for Patients With Chronic Kidney Disease and Cognitive Disorder

Completed·TTaipei Medical University Hospital··NCT07272733·15 enrolled

Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients

Completed·FFresenius·Phase 1/2·NCT03077048·23 enrolled

Diabetic Nephropathy1 trial

Controlled Study to Evaluate Efficacy and Safety of α-KA Tab With Low Protein Diet (LPD) in Delaying the Progress of Type 2 Diabetic Nephropathy (DN)

Completed·FFresenius·Phase 4·NCT00363987·179 enrolled

Dialysis1 trial

Effects of Low Protein Diet Supplemented With Ketoanalogues on Preservation of Kidney Function in Incremental Dialysis

Unknown status·—·Phase 2/3·NCT05030168·50 enrolled

Nephrotic Syndrome1 trial

Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome

Recruiting·MMilitary Institute od Medicine National Research Institute·Phase 3·NCT05716880·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ketosteril. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ketosteril compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ketosteril. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fresenius company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFresenius

Ketosteril

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Chronic Kidney Disease2 trials

Diabetic Nephropathy1 trial

Dialysis1 trial

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News